相关实验视频
Updated: Feb 24, 2026

07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
9.6K
子口服免疫疗法在儿童:一个意大利单一中心的回顾性队列研究
Simona Barni1, Benedetta Pessina1,2, Serena Della Femina2
1Allergy Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
概括
子口服免疫疗法 (H-OIT) 显示出治疗儿科子过敏 (HA) 的前景. 虽然有效,但高停药率和像过敏反应这样的反应需要仔细考虑风险和益处.
科学领域:
- 儿科过敏和免疫学
- 食物过敏治疗 食物过敏治疗
- 免疫疗法研究 免疫疗法研究
背景情况:
- 子过敏 (HA) 对儿童来说是一个重大的健康问题.
- 子口服免疫疗法 (H-OIT) 是一种新兴的治疗策略.
- 评估H-OIT在儿科患者群体中的安全性和有效性至关重要.
研究的目的:
- 评估H-OIT在患有HA的儿童中的安全性和有效性.
- 描述接受H-OIT的儿科患者的临床特征和过敏特征.
- 分析影响H-OIT完成和治疗结果的因素.
主要方法:
- 一项队列研究招募了124名在三级儿科医院接受H-OIT的儿童.
- 收集的数据包括人口统计,病史,过敏测试结果和H-OIT细节.
- 评估的结果包括剂量升级,停止治疗,反应和过敏标志物的变化.
主要成果:
- 43.5%的患者达到目标维持剂量,而25%的患者仍然服用部分剂量.
- 治疗中断率为31.5%,其主要原因是失去随访.
- 82.3%的人在H-OIT期间出现反应,大多是轻微的,但8.8%的人有过敏反应.
- 观察到刺针测试直径和Cora14IgE水平的显著减少.
- 一个积极的家族病史的亚托皮与完成H-OIT的几率较低有关.
结论:
- H-OIT是儿童HA的潜在有效治疗方法,尽管对坚持和反应存在挑战.
- 很大一部分儿童达到部分或全部维持剂量.
- 安全性概况通常是可以接受的,但过敏反应需要对家庭进行仔细的风险益处评估.
- 需要进一步的研究来优化H-OIT协议并改善患者的遵守.
相关概念视频
Bioavailability Study Design: Healthy Subjects Versus Patients
190
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
190
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
353
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
353
Bioavailability Study Design: Single Versus Multiple Dose Studies
283
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
283
Clinical Trials
10.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.9K
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
59
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
59
Pharmacokinetics in Pediatric Patients: Drug Metabolism
276
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
276

